A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (NCT03165734)
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)
🩺 Plain-English Summary (8th-Grade Level)
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (207 Sites)
Showing the first 25 of 207 sites.
- University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center — Birmingham, Alabama
- Mayo Clinic Hospital — Phoenix, Arizona
- City of Hope — Duarte, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA David Geffen School of Medicine — Los Angeles, California
- University of Colorado Cancer Center — Aurora, Colorado
- Rocky Mountain Cancer Centers (US Oncology/McKesson) — Boulder, Colorado
- Yale School of Medicine — New Haven, Connecticut
- Georgetown University Hospital — Washington D.C., District of Columbia
- George Washington University-Medical Faculty Associates — Washington D.C., District of Columbia
- Cleveland Clinic Florida — Weston, Florida
- Northwestern Memorial Hospital — Chicago, Illinois
- Rush University Medical Center — Chicago, Illinois
- The University of Chicago Medical Center — Chicago, Illinois
- University of Kansas Cancer Center and Medical Pavilion — Westwood, Kansas
- Ochsner Medical Center — New Orleans, Louisiana
- Saint Agnes Hospital — Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland
- American Oncology Partners of Maryland, PA — Bethesda, Maryland
- Regional Cancer Care Associates LLC - CCBD Division — Bethesda, Maryland
- Maryland Oncology Hematology, PA- Columbia — Columbia, Maryland
- Michigan Medicine Hematology Clinic-Rogel Cancer Center — Ann Arbor, Michigan
- Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
- Washington University School of Medicine-Siteman Cancer Center — St Louis, Missouri
- Comprehensive Cancer Centers of Nevada- Twain Office — Las Vegas, Nevada
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Myelofibrosis
- CINC424A2X01B Rollover Protocol — Darlinghurst, New South Wales
- Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis — Seattle, Washington
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk — Los Angeles, California
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — Seattle, Washington
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis — Ann Arbor, Michigan
- Myeloproliferative Neoplasms (MPNs) Patient Registry — Toronto, Ontario
Explore by condition: All Primary Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.